Y-27632 dihydrochloride is an orally active and ATP-competitive ROCK (Rho-kinase) inhibitor (ROCK-I Ki=220 nM; ROCK-II Ki=300 nM). Y-27632 dihydrochloride shows antiepileptic effects[1][2][3][4].
Resulted in the up-regulation of NSE, MAP-2 and nestin protein levels by 25.3, 3.1 and 2.5 fold, respectively, compared to control cells not treated by Y-27632.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
Male Wistar rats injected with dimethylnitrosamine[1]
Dosage:
30 mg/kg
Administration:
Oral gavage; 30 mg/kg; once daily; 4 weeks
Result:
Decreased the occurrence of dimethylnitrosamine-induced hepatic fibrosis and reduced the collagen and hydroxyproline content and α-smooth muscle actin expression in the liver.